Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044269 | 1.00 | CYP4F2 (0.44) | CYP4F2CYP4A11TBXAS1FFAR1CPT2 | |
| SCHEMBL3049340 | 0.98 | FFAR1 (0.44) | CYP4F2CYP4A11TBXAS1FFAR1CPT2 | |
| SCHEMBL3045370 | 0.93 | FFAR1 (0.45) | CYP4F2CYP4A11TBXAS1FFAR1CPT2 | |
| SCHEMBL6267147 | 0.93 | FFAR1 (0.47) | CYP4F2CYP4A11TBXAS1FFAR1CPT2 | |
| SCHEMBL3037916 | 0.92 | GPR84 (0.53) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL3039584 | 0.92 | GPR84 (0.48) | CYP4F2CYP4A11TBXAS1FFAR1CPT2 | |
| SCHEMBL6696708 | 0.87 | GPR84 (0.54) | CYP4F2CYP4A11TBXAS1FFAR1CPT2 | |
| SCHEMBL6695817 | 0.87 | GPR84 (0.54) | CYP4F2CYP4A11TBXAS1FFAR1CPT2 | |
| SCHEMBL3045517 | 0.86 | TDP1 (0.60) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL3042960 | 0.86 | TDP1 (0.60) | CYP4F2CYP4A11FFAR1CPT2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | ESPERION THERAPEUTICS, INC. | 2010-10-07 | — | — | US | claimed |
| US-7709515-B2 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. (US) | 2010-05-04 | — | — | US | claimed |
| EP-1862444-A2 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics, Inc. (US) | 2007-12-05 | — | — | EP | claimed |
| EP-1849760-A1 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics Inc. (US) | 2007-10-31 | — | — | EP | claimed |
| US-7192940-B2 | Ether compounds | ESPERION THERAPEUTICS, INC. (US) | 2007-03-20 | — | — | US | claimed |
| US-20050119333-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. | 2005-06-02 | — | — | US | claimed |
| US-20050004082-A1 | Therapy for cardiovascular, metabolism and cholesterol disorders | ESPERION THERAPEUTICS, INC. | 2005-01-06 | — | — | US | claimed |
| US-6831105-B2 | For therapy and prophylaxis of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders | ESPERION THERAPEUTICS, INC. | 2004-12-14 | — | — | US | claimed |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. | 2003-08-07 | — | — | US | claimed |
| EP-1204626-A4 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS INC (US) | 2003-05-07 | — | — | EP | claimed |
| US-20030065195-A1 | Ether compounds | ESPERION THERAPEUTICS, INC. | 2003-04-03 | — | — | US | claimed |
| US-6506799-B1 | Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and | ESPERION THERAPEUTICS, INC. | 2003-01-14 | — | — | US | claimed |
| JP-2002541129-A | — | — | 2002-12-03 | — | — | JP | claimed |
| US-6459003-B1 | ETHER COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS, METABOLISM DISORDERS AND CHOLESTEROL DISORDERS | ESPERION THERAPEUTICS, INC. | 2002-10-01 | — | — | US | claimed |
| EP-1204626-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Esperion Therapeutics Inc. (US) | 2002-05-15 | — | — | EP | claimed |
| WO-2000059855-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS, INC. (US) | 2000-10-12 | — | — | WO | claimed |
| EP-1862444-A2 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1849760-A1 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1204626-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Esperion Therapeutics Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2000059855-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS, INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | GPR119, ECHS1, PNLIP | CYP4F2 483/4885CYP4A11 35/4885TBXAS1 250/4885 |
| US-20030065195-A1 | Ether compounds | GPR119, PPARG, PNLIP | CYP4F2 715/4885CYP4A11 93/4885TBXAS1 475/4885 |
| US-20050004082-A1 | Therapy for cardiovascular, metabolism and cholesterol disorders | GPR119, NR1H2, PC | CYP4F2 527/4885CYP4A11 105/4885TBXAS1 466/4885 |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | GPR119, ECHS1, PNLIP | CYP4F2 483/4885CYP4A11 35/4885TBXAS1 250/4885 |
| US-20050119333-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | GPR119, ECHS1, PNLIP | CYP4F2 483/4885CYP4A11 35/4885TBXAS1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.